Moderna is a US biotechnology company. Its COVID-19 vaccine was approved for use in the UK on 8 January, 2021 - the third vaccine to get this approval. Moderna is expanding its production capability in Europe and UK supplies are expected in spring 2021. Moderna's share price rose after it announced encouraging early results from vaccine trials in November 2020, so news of an approved vaccine could see the share price rise further. The company uses a molecule called "messenger RNA" (or mRNA), which exists in the cells in your body, to produce medicines. We've compiled what you need to know about how to buy Moderna shares.
Best for
0% commission
Best for
Beginner investments
Best for
Beginners
BEST FOR
US shares
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 - £9.99 | No minimum | £4.77 £812.49 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £4.04 £811.76 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £12.31 £820.04 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £4.04 £811.76 total |
Capital at risk |
|
Not yet rated | £0 | No minimum | £4.04 £811.76 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £20.03 £827.75 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.91 £810.63 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
August 18, 2023: Moderna announced positive results for its updated COVID vaccine and the stock price has responded positively.
August 8, 2023: Moderna stock has dropped 6% yesterday and is down by over 13% in the past week as the company missed earnings expectations, with a reported earnings per share (EPS) of -$3.62.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Moderna P/E ratio, PEG ratio and EBITDA
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Moderna shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $876 million (£0.0 million).
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
Join 50,000 subscribers who are notified about expert share tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Kyocera? We explain how and compare a range of providers that can give you access to many brands, including Kyocera.
Ever wondered how to buy shares in General Finance? We explain how and compare a range of providers that can give you access to many brands, including General Finance.
Ever wondered how to buy shares in Baringsorate Investors? We explain how and compare a range of providers that can give you access to many brands, including Baringsorate Investors.
Ever wondered how to buy shares in 1st Source? We explain how and compare a range of providers that can give you access to many brands, including 1st Source.
Ever wondered how to buy shares in Eargo? We explain how and compare a range of providers that can give you access to many brands, including Eargo.
Ever wondered how to buy shares in MediaAlpha? We explain how and compare a range of providers that can give you access to many brands, including MediaAlpha.
Ever wondered how to buy shares in Casper Sleep? We explain how and compare a range of providers that can give you access to many brands, including Casper Sleep.
Ever wondered how to buy shares in X Financial? We explain how and compare a range of providers that can give you access to many brands, including X Financial.
Ever wondered how to buy shares in Capital City Bank Group? We explain how and compare a range of providers that can give you access to many brands, including Capital City Bank Group.
Ever wondered how to buy shares in Genpact? We explain how and compare a range of providers that can give you access to many brands, including Genpact.